

Name of journal: World Journal of Meta-Analysis

ESPS Manuscript NO: 20949

Manuscript Type: META-ANALYSIS

Risk of pancreatic adverse events <sup>6</sup> associated with the use of glucagon-like peptide-1 receptor agonist and dipeptidyl peptidase-4 inhibitor drugs: A systematic review and meta-analysis of randomized trials

Hasan M Shihab, Tokunbo Akande, Kacie Armstrong, Sonal Singh, Yoon Kong Loke

Abstract

### Match Overview

1	<b>CrossCheck</b> 101 words Vaniyapong, Tanat, Wilaiwan Chongruksut, Kittipan Rerkasem, and Kittipan Rerkasem. "Local versus general ..."	2%
2	<b>Internet</b> 73 words crawled on 19-Jul-2015 <a href="http://archinte.jamanetwork.com">archinte.jamanetwork.com</a>	2%
3	<b>CrossCheck</b> 35 words Alves, Carlos, Francisco Batel-Marques, and Ana F. Mac edo. "A meta-analysis of serious adverse events repor ..."	1%
4	<b>Internet</b> 32 words crawled on 21-May-2015 <a href="http://www.ncbi.nlm.nih.gov">www.ncbi.nlm.nih.gov</a>	1%
5	<b>Internet</b> 27 words crawled on 05-Aug-2010 <a href="http://www.mybiosource.com">www.mybiosource.com</a>	1%
6	<b>Internet</b> 25 words crawled on 29-May-2015 <a href="http://www.bmj.com">www.bmj.com</a>	1%

## Do GLP-1–Based Therapies Increase Cancer Risk? - Diabetes Care

[care.diabetesjournals.org/content/36/Supplement\\_2/S245.long](http://care.diabetesjournals.org/content/36/Supplement_2/S245.long)

Furthermore, in rodents like mice and rats, stimulating the GLP-1 receptor raises ... of acute pancreatitis associated with the use of exenatide as an antidiabetes ... per group (GLP-1 receptor agonist, DPP-4 inhibitor, or control medication). ..... the FDA Adverse Event Reporting System, helped with analyses, and reviewed the....

## Safety of dipeptidyl peptidase 4 inhibitors: a perspective review

[www.ncbi.nlm.nih.gov/pmc/articles/PMC4110853/](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4110853/)

Hypoglycemic risk was similar to placebo when a DPP-4 inhibitor was used as ... drug-related adverse events, including hypersensitivity reactions [Lo Re et al. ... Pancreas-related adverse events reported after authorization of DPP-4 ..... of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review.

## Choosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors ...

[www.hindawi.com/journals/jnme/2012/381713/](http://www.hindawi.com/journals/jnme/2012/381713/)

21 Sep 2012 ... Pharmacology of GLP-1 Receptor Agonists . DPP-4 Inhibitors ... through systematic reviews and meta-analyses of incretin studies as very ... Both drugs were tolerated well by subjects and resulted in similar weight .... insulin therapy comes with significant risks of adverse events such as hypoglycaemia.

## Incretin treatment and risk of pancreatitis in patients with type 2 ...



Risk of pancreatic adverse events associated with the use of glucagon-like p

[网页](#)[新闻](#)[图片](#)[视频](#)[更多](#)[搜索工具](#)

找到约 18,500 条结果 (用时 0.90 秒)

### Safety of dipeptidyl peptidase 4 inhibitors: a perspective ...

[www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov) > ... > PubMed Central (PMC) ▾ [翻译此页](#)

作者: T Karagiannis - 2014 - 被引用次数: 23 - 相关文章

Dipeptidyl peptidase 4 (DPP-4) inhibitors are a relatively new class of oral ... Keywords: adverse effects, drug safety, dipeptidyl peptidase 4 inhibitors, pancreatitis, type 2 ... metformin or a GLP-1 agonist than a DPP-4 inhibitor [Karagiannis et al. .... receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review.

### Incretin treatment and risk of pancreatitis in patients with ...

[www.bmj.com/content/348/bmj.g2366](http://www.bmj.com/content/348/bmj.g2366) ▾ [翻译此页](#)

作者: L Li - 2014 - 被引用次数: 67 - 相关文章

2014年4月15日 - Ling Li, research associate<sup>12</sup>; Jiantong Shen, lecturer<sup>3</sup>, ... Design Systematic review and meta-analysis. ... receptor agonists or dipeptidyl peptidase-4 (DPP-4) inhibitors in ... Evidence from randomised controlled trials has shown that GLP-1 ... Fig 2 Risk of pancreatitis events between patients with type 2 ...

### Do GLP-1-Based Therapies Increase Cancer Risk?

[care.diabetesjournals.org/content/36/Supplement\\_2/S245.full](http://care.diabetesjournals.org/content/36/Supplement_2/S245.full) ▾ [翻译此页](#)

作者: MA Nauck - 2013 - 被引用次数: 32 - 相关文章

For the purpose of this review, GLP-1-based therapies are GLP-1 receptor agonists ... and others or dipeptidyl peptidase 4 (DPP-4) inhibitors such as sitagliptin ... 30 cases of



[网页](#)[新闻](#)[图片](#)[视频](#)[更多 ▾](#)[搜索工具](#)

找到约 16,900 条结果 (用时 0.86 秒)

### Safety of dipeptidyl peptidase 4 inhibitors: a perspective ...

[www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov) > ... > PubMed Central (PMC) ▾ [翻译此页](#)

作者: T Karagiannis - 2014 - 被引用次数: 25 - 相关文章

Dipeptidyl peptidase 4 (DPP-4) inhibitors are a relatively new class of oral ... Keywords:

adverse effects, drug safety, dipeptidyl peptidase 4 inhibitors, pancreatitis, type 2 ...

metformin or a GLP-1 agonist than a DPP-4 inhibitor [Karagiannis et al. .... receptor

agonists and DPP-4 inhibitors: meta-analysis and systematic review.

### Incretin treatment and risk of pancreatitis in patients with ...

[www.ncbi.nlm.nih.gov/pubmed/24736555](http://www.ncbi.nlm.nih.gov/pubmed/24736555) ▾ [翻译此页](#)

作者: L Li - 2014 - 被引用次数: 71 - 相关文章

2014年4月15日 - OBJECTIVE: To investigate the risk of pancreatitis associated with the

use of ... DESIGN: Systematic review and meta-analysis. ... peptide-1 (GLP-1) receptor

agonists or dipeptidyl peptidase-4 (DPP-4) inhibitors in adults ... A modified Cochrane

tool for randomised controlled trials and a modified version of ...

### Glucagon-like peptide-1 receptor agonists for the treatment ...

[www.uptodate.com/.../glucagon-like-peptide-1-receptor-agonis...](http://www.uptodate.com/.../glucagon-like-peptide-1-receptor-agonis...) ▾ [翻译此页](#)

2015年9月9日 - (See "Dipeptidyl peptidase 4 (DPP-4) inhibitors for the treatment of type

2 ... with GLP-1 and its receptor agonists is associated with weight loss, even ... on

weight loss: systematic review and meta-analyses of randomised controlled trials. ... Type

2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.

### Do GLP-1–Based Therapies Increase Cancer Risk?

[care.diabetesjournals.org/content/36/Supplement\\_2/S245.full](http://care.diabetesjournals.org/content/36/Supplement_2/S245.full) ▾ [翻译此页](#)

作者: MA Nauck - 2013 - 被引用次数: 37 - 相关文章

For the purpose of this review, GLP-1-based therapies are GLP-1 receptor agonists